Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
Autor: | Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Soo Jung Park, Yong Il Lee, Yehyun Park |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Hepatology business.industry Hazard ratio Gastroenterology medicine.disease Logistic regression Ulcerative colitis Confidence interval Infliximab 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Adalimumab 030211 gastroenterology & hepatology Colitis Adverse effect business medicine.drug |
Zdroj: | Gut and Liver. 15:232-242 |
ISSN: | 2005-1212 1976-2283 |
Popis: | Background/Aims: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no head-to-head comparison of treatment efficacy and outcomes between the two agents. The aim of this study was to compare the efficacy and long-term outcomes of infliximab versus adalimumab treatment in biologic-naive patients with UC. Methods: We retrospectively analyzed the records of 113 biologic-naive patients with UC who were treated between September 2012 and December 2017 (the infliximab group [n=83] and the adalimumab group [n=30]). We compared remission and response rates between these groups at 8 and 52 weeks. We used Kaplan-Meier curves to compare long-term outcomes, and logistic regression analysis and Cox-proportional hazard regression models to assess factors affecting outcomes. Results: The median follow-up duration was 25.8 months. Baseline clinical characteristics were similar between groups. There were no significant differences between the two groups in the rate of clinical remission or clinical response at 8 or 52 weeks. Multivariate analyses also showed that long-term outcomes were not significantly different (adjusted hazard ratio [HR], 1.45; 95% confidence interval [CI], 0.81 to 2.56; p=0.208). An elevated C-reactive protein level (greater than 5 mg/L) was a significant predictive factor for poor outcomes (adjusted HR, 2.25; 95% CI, 1.37 to 3.70; p=0.001). During the follow-up period, the rates of adverse event were not significantly different between the two groups (p=0.441). Conclusions: In our study, infliximab and adalimumab had similar treatment efficacy and long-term outcomes in biologic-naive patients with moderate to severe UC. (Gut Liver 2021;15:232- 242) |
Databáze: | OpenAIRE |
Externí odkaz: |